StockData
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. (XBIO) stock

XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3067% below fair value
$1.61+0.12 (+8.05%)

Close on Nov 17, 2026Market cap $3.77MP/E –Yield –

Xenetic Biosciences enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Xenetic Biosciences's enterprise value was -$2.10M on Nov 11, 2026, against -$65.77K a year earlier. Over the last 5 years it ranged from -$10.85M to $3.35M, with a median of -$2.10M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$2.10M–
2025Dec 31, 2025-$775.16K–
2024Dec 31, 2024-$686.43K–
2023Dec 29, 2023-$4.49M–
2022Dec 30, 2022-$10.85M–
2021Dec 31, 2021-$2.43M-142.1%
2020Dec 31, 2020$5.79M–
2019Dec 31, 2019-$3.93M-128.6%
2018Dec 31, 2018$13.74M-13.9%
2017Dec 29, 2017$15.96M-54.9%
2016Dec 30, 2016$35.43M–

More Xenetic Biosciences figures

See a number that looks wrong?